Compare Abbott Laboratories (ABT) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Standard Lithium Ltd — how do they compare? Abbott Laboratories trades at $95.31 (market cap $166.94B), while Standard Lithium Ltd trades at $2.51 (market cap $592.60M). The key difference: Abbott Laboratories is far larger — about 281.7× Standard Lithium Ltd's market cap, and Abbott Laboratories pays a 2.63% dividend while Standard Lithium Ltd pays none. Which is the better fit depends on your goals.
| ABT | SLI | |
|---|---|---|
Market Cap | $166.94B | $592.60M |
Sector | Health | Basic Materials |
52-Week High | $136.62 | $5.65 |
52-Week Low | $82.57 | $2.29 |
Enterprise Value | $193.69B | $451.80M |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Standard Lithium (SLI) trades at $2.68, down 1.47% on the day, with a bearish technical signal from moving averages despite some bullish oscillators. The company reported a net loss of $48.40 million in 2025, with negative ROE and ROA, but maintains a P/B ratio of 1.8. Recent news highlights progress on its South West Arkansas lithium project, including a $225 million DOE grant and key construction contracts, positioning it for a final investment decision in 2026.
The investment case hinges on successful project execution and lithium market dynamics, with 100% analyst buy ratings signaling strong growth potential. Key risks include persistent negative cash flow from operations, high capital expenditures, and execution delays. Upside depends on timely project completion and favorable lithium pricing, while downside risks involve funding gaps and operational setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
